404 related articles for article (PubMed ID: 26739763)
1. Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes.
Clark DJ; Fondrie WE; Yang A; Mao L
J Proteomics; 2016 Feb; 133():161-169. PubMed ID: 26739763
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer.
Niu L; Song X; Wang N; Xue L; Song X; Xie L
Cancer Sci; 2019 Jan; 110(1):433-442. PubMed ID: 30407700
[TBL] [Abstract][Full Text] [Related]
3. Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.
Clark DJ; Mei Y; Sun S; Zhang H; Yang AJ; Mao L
Theranostics; 2016; 6(1):65-77. PubMed ID: 26722374
[TBL] [Abstract][Full Text] [Related]
4. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
Shao N; Song L; Sun X
Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions.
Park JO; Choi DY; Choi DS; Kim HJ; Kang JW; Jung JH; Lee JH; Kim J; Freeman MR; Lee KY; Gho YS; Kim KP
Proteomics; 2013 Jul; 13(14):2125-34. PubMed ID: 23585444
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2.
Wang D; Zhao C; Xu F; Zhang A; Jin M; Zhang K; Liu L; Hua Q; Zhao J; Liu J; Yang H; Huang G
Theranostics; 2021; 11(6):2860-2875. PubMed ID: 33456577
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
[TBL] [Abstract][Full Text] [Related]
8. Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.
Schweppe DK; Rigas JR; Gerber SA
J Proteomics; 2013 Oct; 91():286-96. PubMed ID: 23911959
[TBL] [Abstract][Full Text] [Related]
9. FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sites.
Thuya WL; Kong LR; Syn NL; Ding LW; Cheow ESH; Wong RTX; Wang T; Goh RMW; Song H; Jayasinghe MK; Le MT; Hu JC; Yong WP; Lee SC; Wong AL; Sethi G; Hung HT; Ho PC; Thiery JP; Sze SK; Guo T; Soo RA; Yang H; Lim YC; Wang L; Goh BC
Theranostics; 2023; 13(2):621-638. PubMed ID: 36632230
[No Abstract] [Full Text] [Related]
10. Unique Protein Profiles of Extracellular Vesicles as Diagnostic Biomarkers for Early and Advanced Non-Small Cell Lung Cancer.
An T; Qin S; Sun D; Huang Y; Hu Y; Li S; Zhang H; Li B; Situ B; Lie L; Wu Y; Zheng L
Proteomics; 2019 Jun; 19(12):e1800160. PubMed ID: 30950185
[TBL] [Abstract][Full Text] [Related]
11. Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance.
Lobb RJ; van Amerongen R; Wiegmans A; Ham S; Larsen JE; Möller A
Int J Cancer; 2017 Aug; 141(3):614-620. PubMed ID: 28445609
[TBL] [Abstract][Full Text] [Related]
12. Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.
Böttger F; Schaaij-Visser TB; de Reus I; Piersma SR; Pham TV; Nagel R; Brakenhoff RH; Thunnissen E; Smit EF; Jimenez CR
J Proteomics; 2019 Mar; 196():106-119. PubMed ID: 30710758
[TBL] [Abstract][Full Text] [Related]
13. Preferential Localization of MUC1 Glycoprotein in Exosomes Secreted by Non-Small Cell Lung Carcinoma Cells.
Pan D; Chen J; Feng C; Wu W; Wang Y; Tong J; Zhou D
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646616
[TBL] [Abstract][Full Text] [Related]
14. SWATH™- and iTRAQ-based quantitative proteomic analyses reveal an overexpression and biological relevance of CD109 in advanced NSCLC.
Zhang F; Lin H; Gu A; Li J; Liu L; Yu T; Cui Y; Deng W; Yan M; Li J; Yao M
J Proteomics; 2014 May; 102():125-36. PubMed ID: 24667143
[TBL] [Abstract][Full Text] [Related]
15. Comparative proteome analysis across non-small cell lung cancer cell lines.
Grundner-Culemann K; Dybowski JN; Klammer M; Tebbe A; Schaab C; Daub H
J Proteomics; 2016 Jan; 130():1-10. PubMed ID: 26361996
[TBL] [Abstract][Full Text] [Related]
16. Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach.
Pan ST; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():937-68. PubMed ID: 25733813
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
18. Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.
Tauro BJ; Greening DW; Mathias RA; Mathivanan S; Ji H; Simpson RJ
Mol Cell Proteomics; 2013 Mar; 12(3):587-98. PubMed ID: 23230278
[TBL] [Abstract][Full Text] [Related]
19. Roles of exosomes in the carcinogenesis and clinical therapy of non-small cell lung cancer.
Liu S; Zhan Y; Luo J; Feng J; Lu J; Zheng H; Wen Q; Fan S
Biomed Pharmacother; 2019 Mar; 111():338-346. PubMed ID: 30590322
[TBL] [Abstract][Full Text] [Related]
20. Pigment epithelium-derived factor inhibits lung cancer migration and invasion by upregulating exosomal thrombospondin 1.
Huang WT; Chong IW; Chen HL; Li CY; Hsieh CC; Kuo HF; Chang CY; Chen YH; Liu YP; Lu CY; Liu YR; Liu PL
Cancer Lett; 2019 Feb; 442():287-298. PubMed ID: 30439539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
